Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy

Kitt Falk Petersen(Yale University), Elif A Oral(National Institute of Diabetes and Digestive and Kidney Diseases), Sylvie Dufour(Yale University), Douglas E. Befroy(Howard Hughes Medical Institute), Charlotte E. Ariyan(Yale University), Chunli Yu(Yale University), Gary W. Cline(Yale University), Alex M. DePaoli(Amgen (United States)), Simeon I. Taylor(National Institutes of Health), Phillip Görden(National Institutes of Health), Gerald I. Shulman(Yale University)
Journal of Clinical Investigation
May 15, 2002
Cited by 704Open Access
Full Text

Abstract

Lipodystrophy is a rare disorder that is characterized by selective loss of subcutaneous and visceral fat and is associated with hypertriglyceridemia, hepatomegaly, and disordered glucose metabolism. It has recently been shown that chronic leptin treatment ameliorates these abnormalities. Here we show that chronic leptin treatment improves insulin-stimulated hepatic and peripheral glucose metabolism in severely insulin-resistant lipodystrophic patients. This improvement in insulin action was associated with a marked reduction in hepatic and muscle triglyceride content. These data suggest that leptin may represent an important new therapy to reverse the severe hepatic and muscle insulin resistance and associated hepatic steatosis in patients with lipodystrophy.


Related Papers

No related papers found

Powered by citation graph analysis